Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Abstract

Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)